Overexpression of antiapoptotic members of the Bcl-2 family proteins, such as Bcl-xL and Mfl- 1, has been shown to be involved in resistance to chemotherapeutic drugs in many forms of cancers. Recent efforts from the Abbott Laboratories resulted in the development of the acylsulfonamide compound and clinical candidate that targets selectively Bcl-2, Bcl-xL, and Bcl-w while it is not active against Mcl-1 and Bfl-1. However, early clinical and preclinical ...
